XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2018
Segment information | a. Segment information:
|  | North America |  |  | Europe |  |  | Growth Markets |
|  | Three months ended March 31, |  |  | Three months ended March 31, |  |  | Three months ended March 31, |
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
|  | (U.S. $ in millions) |  |  | (U.S. $ in millions) |  |  | (U.S. $ in millions) |
Revenues |  | $ | 2,531 |  |  | $ | 3,240 |  |  | $ | 1,442 |  |  | $ | 1,341 |  |  | $ | 750 |  |  | $ | 718 |
Gross profit |  |  | 1,432 |  |  |  | 2,080 |  |  |  | 797 |  |  |  | 734 |  |  |  | 313 |  |  |  | 292 |
R&D expenses |  |  | 188 |  |  |  | 267 |  |  |  | 73 |  |  |  | 106 |  |  |  | 24 |  |  |  | 47 |
S&M expenses |  |  | 305 |  |  |  | 441 |  |  |  | 255 |  |  |  | 279 |  |  |  | 134 |  |  |  | 158 |
G&A expenses |  |  | 126 |  |  |  | 139 |  |  |  | 91 |  |  |  | 79 |  |  |  | 41 |  |  |  | 48 |
Other income |  |  | (102 | ) |  |  | (73 | ) |  |  | 1 |  |  |  | 2 |  |  |  | (8 | ) |  |  | (1 | )
Segment profit |  | $ | 915 |  |  | $ | 1,306 |  |  | $ | 377 |  |  | $ | 268 |  |  | $ | 122 |  |  | $ | 40 |
|  | Three months ended March 31, |
|  | 2018 |  |  | 2017 |
|  | (U.S.$ in millions) |
North America profit |  | $ | 915 |  |  | $ | 1,306 |
Europe profit |  |  | 377 |  |  |  | 268 |
Growth Markets profit |  |  | 122 |  |  |  | 40 |
Total segment profit |  |  | 1,414 |  |  |  | 1,614 |
Profit of other activities |  |  | 21 |  |  |  | 7 |
|  |  | 1,435 |  |  |  | 1,621 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |
Amortization |  |  | 310 |  |  |  | 320 |
Other asset impairments, restructuring and other items |  |  | 707 |  |  |  | 240 |
Goodwill impairment |  |  | 180 |  |  |  | — |
Gain on divestitures, net of divestitures related costs |  |  | (93 | ) |  |  | — |
Inventory step-up |  |  | — |  |  |  | 64 |
Other R&D expenses |  |  | 22 |  |  |  | — |
Costs related to regulatory actions taken in facilities |  |  | 1 |  |  |  | 34 |
Legal settlements and loss contingencies |  |  | (1,278 | ) |  |  | 20 |
Other unallocated amounts |  |  | 61 |  |  |  | 48 |
Consolidated operating income |  |  | 1,525 |  |  |  | 895 |
Financial expenses, net |  |  | 271 |  |  |  | 207 |
Consolidated income before income taxes |  | $ | 1,254 |  |  | $ | 688 |
Schedule of Net Sales by Product Line | b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for the three months ended March 31, 2018 and 2017:
|  | Three months ended March 31, |
|  | 2018 |  |  | 2017 |
|  | (U.S.$ in millions) |
North America segment |  |  |  |  |  |  |  |
Generic products |  | $ | 1,088 |  |  | $ | 1,415 |
COPAXONE |  |  | 476 |  |  |  | 797 |
BENDEKA / TREANDA |  |  | 181 |  |  |  | 156 |
ProAir |  |  | 130 |  |  |  | 121 |
QVAR |  |  | 107 |  |  |  | 84 |
AUSTEDO |  |  | 30 |  |  |  | — |
Distribution |  |  | 331 |  |  |  | 295 |
|  | Three months ended March 31, |
|  | 2018 |  |  | 2017 |
|  | (U.S.$ in millions) |
Europe segment |  |  |  |  |  |  |  |
Generic products |  | $ | 997 |  |  | $ | 850 |
COPAXONE |  |  | 153 |  |  |  | 152 |
Respiratory products |  |  | 113 |  |  |  | 84 |
|  | Three months ended March 31, |
|  | 2018 |  |  | 2017 |
|  | (U.S.$ in millions) |
Growth Markets segment |
Generic products |  | $ | 488 |  |  | $ | 486 |
COPAXONE |  |  | 16 |  |  |  | 21 |
Distribution |  |  | 153 |  |  |  | 125 |

X
- Definition A schedule of net sales by major product line. + References No definition available. + Details
Name: | teva_SalesByProductLineTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration